Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states

Journal of Infectious Diseases

Volumn 175, Issue 3, 1997, Pages 716-719

  Astier Gin, T ^a   Portail, J P ^b   Londos Gagliardi, D ^b   Moynet, D ^b   Blanchard, S ^b   Dalibart, R ^b   Pouliquen, J F ^b   Georges Courbot, M C ^b   Hajjar, C ^b   Sainte Foie, S ^b   Guillemain, B ^b  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANTIGEN BINDING; ARTICLE; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE ASSAY; REPORTER GENE; SJOEGREN SYNDROME; SPASTIC PARAPLEGIA;

EID: 16944364670     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.3.716     Document Type: Article

References (16)

1. Yoshida M, Miyoshi J, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982;79:2031-5.
2. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-Lymphotropic virus type-1 in patients with tropical spastic paraparesis. Lancet 1985;11:407-10.
3. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031-2.
4. Hajjar C, Sainte-Foie S, Savin J, et al. Infection à HTLV-I et syndrome sec. J Fr Ophtalmol 1995;18:597-602.
5. Nagy K, Clapham P, Cheingsong-Popov R, Weiss RA. Human T-cell leukemia virus type I: induction of syncytia and inhibition by patient sera. Int J Cancer 1983;32:321-8.
6. Kataoka R, Takehara N, Iwahara Y, et al. Transmission of HTLV-I by blood transfusion and its prevention by passive immunization in rabbit. Blood 1990;76:1657-61.
7. Hart MK, Palker TJ, Haynes BF. Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infection. In: Powel MF, Newman MJ, eds. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995;821-45.
8. Astier-Gin T, Portail JP, Lafond F, Guillemain B. Identification of HTLV-I or HTLV-II infected cells by cocultivation with BHK-21 cells stably transfected with a LTR-LacZ gene construct. J Virol Methods 1995;51: 19-30.
9. Londos-Gagliardi D, Dalibart R, Geoffre S, et al. Immunogenicity of variable regions of the surface envelope glycoprotein of HTLV-I and identification of new major epitopes in the 239-261 region. AIDS Res Hum Retroviruses 1996;12:941-9.
10. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the lymphoma study group (1984-1987). Br J Haematol 1991;79:437.
11. Wolfson M, Lev M, Avinoah I, et al. Stimulation of virus production and induction of self-syncytium formation in human T-cell leukemia virus type 1 and type II-infected T cells by 12-O-tetradecanoylphorbol-13-acetate. J Virol 1994;68:4695-9.
12. Nussbaum O, Broder CC, Berger EA. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol 1994;68:5411-22.
13. Edouard E, Londos-Gagliardi D, Busetta B, et al. Recognition by human sera of a variable region of the surface glycoprotein of HTLV-I. Leukemia 1994;8:565-7.
14. Minagawa H, Yoshida T, Itoyama Y, Mora CA, Albert P, Mori R. Neutralizing antibodies against HTLV-I in HTLV-I associated myelopathy/ tropical spastic paraparesis (HAM/TSP) patients and asymptomatic carriers. Neurology 1992;42:2210-2.
15. Inoue Y, Kuroda N, Shiraki H, Sato H, Maeda Y. Neutralizing activity of human antibodies against the structural protein of human T-cell lymphotropic virus type I. Int J Cancer 1992;52:877-80.
16. Schulz TF, Calabro ML, Hoad JG, et al. HTLV-I envelope sequences from Brazil, the Caribbean, and Romania: clustering of sequences according to geographic origin and variability in an antibody epitope. Virology 1991;184:483-91.